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Abstract  
 
Background 
The peptide hormone ghrelin has many important physiological and 
pathophysiological roles, including the stimulation of growth hormone (GH) release, 
appetite regulation, gut motility and proliferation of cancer cells. We previously 
identified a gene on the opposite strand of the ghrelin gene, ghrelinOS (GHRLOS), 
which spans the promoter and untranslated regions of the ghrelin gene (GHRL). Here 
we further characterise GHRLOS.  
Results 
We have described GHRLOS mRNA isoforms that extend over 1.4 kb of the promoter 
region and 106 nucleotides of exon 4 of the ghrelin gene, GHRL. These GHRLOS 
transcripts initiate 4.8 kb downstream of the terminal exon 4 of GHRL and are present 
in the 3’ untranslated exon of the adjacent gene TATDN2 (TatD DNase domain 
containing 2). Interestingly, we have also identified a putative non-coding TATDN2-
GHRLOS chimaeric transcript, indicating that GHRLOS RNA biogenesis is extremely 
complex. Moreover, we have discovered that the 3’ region of GHRLOS is also 
antisense, in a tail-to-tail fashion to a novel terminal exon of the neighbouring SEC13 
gene, which is important in protein transport. Sequence analyses revealed that 
GHRLOS is riddled with stop codons, and that there is little nucleotide and amino-
acid sequence conservation of the GHRLOS gene between vertebrates. The gene spans 
44 kb on 3p25.3, is extensively spliced and harbours multiple variable exons. We 
have also investigated the expression of GHRLOS and found evidence of differential 
tissue expression. It is highly expressed in tissues which are emerging as major sites 
of non-coding RNA expression (the thymus, brain, and testis), as well as in the ovary 
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and uterus. In contrast, very low levels were found in the stomach where sense, GHRL 
derived RNAs are highly expressed. 
Conclusion 
GHRLOS RNA transcripts display several distinctive features of non-coding (ncRNA) 
genes, including 5’ capping, polyadenylation, extensive splicing and short open 
reading frames. The gene is also non-conserved, with differential and tissue-restricted 
expression. The overlapping genomic arrangement of GHRLOS with the ghrelin gene 
indicates that it is likely to have interesting regulatory and functional roles in the 
ghrelin axis. 
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Background  
Ghrelin, a hormone with many physiological and pathophysiological roles, was 
initially described as the endogenous ligand for the growth hormone secretagogue 
receptor (GHSR 1a), through which it stimulates the release of growth hormone from 
the anterior pituitary [1]. Ghrelin is primarily produced in the stomach and plays a key 
role in regulating appetite, gut motility and energy balance [2-6]. Ghrelin is also an 
autocrine factor in a number of tissues, as it regulates insulin release and has 
therapeutic potential for inflammatory diseases, heart disease, cancer cachexia, 
diabetes mellitus and obesity [7]. Despite the importance of ghrelin in a range of 
physiological systems and pathophysiological conditions, little is known about the 
regulation of ghrelin synthesis and secretion. We previously identified a gene on the 
opposite strand of the ghrelin gene, ghrelinOS (GHRLOS), which spans the promoter 
and untranslated regions of the ghrelin gene (GHRL) [8]. However, the genomic 
structure, expression pattern and potential function of GHRLOS remains to be 
investigated. It is not known whether GHRLOS RNA species with open reading 
frames exist, or whether GHRLOS is a non-coding RNA gene.  
 
There is strong support for the hypothesis that antisense transcripts  
provide a widespread and important mechanism for the regulation of the human 
genome [9, 10]. Our understanding of the genome is currently undergoing a paradigm 
shift, as a previously hidden and complex layer of antisense and non-coding RNAs is 
emerging, which controls gene transcription and translation through a diverse range of 
mechanisms [11]. Much phenotypic diversity between humans and other species is 
likely to be due to regulation by RNA [12]. 
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In this study, we examined the genomic structure and organisation of GHRLOS. We 
have found that GHRLOS spans approximately 44 kb of genomic DNA and 
transcribes long, 5’ capped, polyadenlyated RNA species that are extensively spliced 
and differentially expressed. High levels of GHRLOS expression occur in the 
emerging non-coding RNA tissues, the brain, testis and thymus. We have also 
examined GHRLOS RNA species in silico, revealing that GHRLOS is a candidate 
non-coding RNA gene. These data provide a strong basis for further functional studies 
to determine whether GHRLOS plays a role in the regulation of ghrelin gene 
expression. 
 
Results 
Characterisation of GHRLOS start sites and alternative splicing 
An initial aim of this study was to characterise GHRLOS in a range of tissues. As we 
have previously demonstrated the expression of GHRLOS mRNA transcripts in the 
human stomach [8], we performed 5’ RLM-RACE (RNA ligase mediated rapid 
amplification of cDNA ends) on this tissue. Unexpectedly, we identified a number of 
new exons (exon I-III) [GenBank:EU789528, EU789529, and EU789530] that are 2.5 
to 4.8 kb upstream of the previously reported GHRLOS transcription start sites [8] in 
exon 4* (4*a-c). To simplify the numbering of GHRLOS exons, the previously 
reported [8] exons 4*, 2**, 2* and -1* have been renamed exon 1 to 4, respectively; 
while the exons upstream of the reported start sites in exon 1 are denoted by Roman 
numerals (I-III). Importantly, in the GHRLOS variants demonstrated via 5’ RLM-
RACE, exon 1 is extended, with a 106 nt region (exon 1d, hereafter termed exon 1)  
overlapping exon 4 of the ghrelin gene (see [Additional file 1]). The novel first exon, 
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exon I, is 51 bp in size (Fig. 1) and overlaps the 3’ untranslated region of the adjacent 
gene, TATDN2 (TatD DNase domain containing 2, also known as hypothetical protein 
KIAA0218) [13]. This gene initiates on the same DNA strand as GHRLOS, 
approximately 32,000 base pairs upstream of the 51 bp exon I of GHRLOS.  
 
In order to determine the polyadenylation site(s) of GHRLOS transcripts, 3’ RACE 
and inverse PCR were conducted using normal stomach and prostate tissues, the 
RWPE-1 prostate cell line and the PC3 prostate cancer cell line (which is derived 
from  prostate cancer cells that have metastasised to the bone). We obtained 3’ RACE 
clones from the PC3 prostate cancer cell line, which demonstrated a 1.4 kb exon 4a 
and a 1.1 kb exon 4b, with the putative polyadenylation signal AAATTA 
[GenBank:EU789531, and EU789532] (Fig. 1). The 3’ RACE data matches a number 
of Expressed Sequence Tags (ESTs) from subchondral bone [GenBank:BM991802], 
foetal liver [GenBank:AI056187], pooled liver and spleen [GenBank:BX118778; 
R01027], Wilms’ tumour (a paediatric cancer of the kidney) [GenBank:AI174574], 
pooled brain cancers [GenBank:AI863058] and high grade serous carcinoma of the 
uterus [GenBank:AI289483]. Moreover, we performed uncapped inverse PCR, and 
sequencing of amplicons from the PC3 cell line revealed a 90 bp exon I and exon 4 
sequence with a 3’ end differing by less than 20 base pairs when compared to the 3’ 
RACE and reported ESTs [GenBank:EU789533]. Interestingly, the putative 3’ end of 
exon 4 corresponds to publicly available Affymetrix Human Exon 1.0 ST array data 
(Exon Cluster ID 183613). Furthermore, all of the amplicons that we obtained were 
followed by a stretch of adenosines at the 3’ ends that are not present in the genomic 
sequence. We, therefore, concluded that we had reached a genuine 3’ end of 
GHRLOS. 
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Complex pattern of GHRLOS variant exon expression 
In order to examine the size and tissue distribution of GHRLOS transcripts, we 
performed Northern blot analysis of mRNA from human stomach and 12 normal, 
human tissues. With a riboprobe designed to span exons I, II, 1 and 2 of GHRLOS, a 
weak, smeared signal ranging from approximately 1.0 to 2.0 kb in size was observed 
in the human stomach upon a lengthened exposure time (data not shown). A riboprobe 
spanning exon 1 alone (a region common to all GHRLOS RNA isoforms) resulted in 
signals ranging from 1.0 to 5.5 kb in size in the pancreas, prostate, salivary gland and 
thymus (Fig. 2). Upon longer exposure times, a smear in the 1.0 to 5.5 kb range was 
seen in all tissues, except for peripheral blood leukocytes and urinary bladder (data 
not shown). This suggests that GHRLOS is a fully processed transcript consisting of 
many mRNA isoforms. 
 
GHRLOS exons are highly polymorphic 
The RACE, inverse RT-PCR and Northern blotting experiments indicate that 
GHRLOS is extensively spliced and that isoforms range greatly in size (from 
approximately 1.0-5.5 kb). To examine the alternative splicing pattern of GHRLOS in 
greater detail, we performed RT-PCR using a range of human tissues and cell lines. 
We used a forward primer common to exon Ia (identified via 5’ RLM-RACE) and a 
reverse primer in a region common to exons 4a and b. Sequence analysis indicated 
that, with the exception of exons 1 and 4, which are common to all known GHRLOS 
isoforms, GHRLOS exons are highly polymorphic in size and exon skipping occurs 
frequently. A representative amplicon banding pattern is shown in [Additional File 2]. 
The highly variable splicing pattern revealed by RT-PCR is consistent with the diffuse 
and broad signal which we detected by Northern blotting. In total we obtained 13 
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different GHRLOS splice variants (Fig. 3). Analysis using GMAP, a genomic 
mapping and alignment program for mRNA and EST sequences [14], indicated that 
all GHRLOS exons are flanked by canonical splice donor and acceptor sites (GT/AG), 
except for exons 3a and 3c where the splice junction is the common non-canonical 
splice pair GC/AG [15]. GHRLOS exons and introns identified are listed in 
[Additional File 3].   
 
Extending the known length of GHRLOS 
Northern blotting demonstrated GHRLOS transcripts 1-5.5 kb in size, however, 
further RT-PCR and 3’ RACE analysis with a number of different primer 
combinations failed to reveal GHRLOS transcripts larger than 2 kb (data not shown). 
For this reason, we hypothesised that the ghrelin antisense gene may extend further 
upstream. Capped RLM-RACE of stomach tissue and uncapped inverse PCR of the 
PC3 prostate cancer cell line (Fig. 1) indicated that a GHRLOS promoter (exon I) was 
present at the very end of the 2 kb 3’ untranslated exon 8 of TATDN2. Moreover, we 
discovered that multiple Cap Analysis of Gene Expression (CAGE) tags are clustered 
approximately 1.5 kb upstream of the GHRLOS transcription start sites found via 5’ 
RLM-RACE. CAGE tags are an average of 20-21 nucleotides and are produced by 
large-scale sequencing of concatemers derived from the 5’ ends of capped mRNA 
[16, 17]. The CAGE method, therefore, detects the most 5’ site of the mRNA 
transcripts (the transcription start site) and gives an unbiased and comprehensive 
picture of the positions and usage of transcription start sites [18]. To confirm if this 
region belongs to GHRLOS, we employed nested RT-PCR using thymus tissue, foetal 
brain tissue and Hep G2 hepatocarcinoma cell line cDNA (with RNA reverse 
transcribed using oligo(dT) primers). The forward primers were present immediately 
 - 9 - 
downstream of the CAGE tag cluster (which is 1.5 kb upstream of the 51 bp exon I of 
GHRLOS) and the reverse primers spanned exon 1 (which is common to all known 
GHRLOS variants). Sequence analysis revealed several novel exon I variants, which 
were approximately 1601 bp, 994 bp and 526 bp in length. All of these variants 
spliced into the expected acceptor site of the 106 bp exon 1 (Fig. 1 and [Additional 
File 4]). The end of the 1601 bp exon I (termed exon Ib) spanned the 51 bp exon I 
(exon Ia) identified via capped RLM-RACE of the stomach, while the other exons (Ic-
d) employed different upstream donor sites, suggesting that they are alternative first 
exons. The data demonstrate that there are at least two first GHRLOS exon regions in 
the untranslated region of TATDN2. This suggests that the GHRLOS promoter is a 
broad-type, TATA-less promoter that initiates transcription at many sites [19]. 
 
The length of GHRLOS transcripts initiating in exon I (present in the 3’ UTR of 
TATDN2) is 1.3-3.6 kb, corresponding in size to the Northern data. However, the 
potential identity of the approximately 5.5 kb transcript seen in the Northern blot with 
a full-length, 106 nt exon 1 probe (Fig. 2) was not determined. After prolonged 
exposure of the Northern blot, the 5.5 kb transcript was observed in all tissues except 
the urinary bladder and uterus (data not shown). TATDN2 is only approximately 1 kb 
upstream of exon II and 4.5 kb from exon 1 of GHRLOS, suggesting that 
transcription-induced chimaeras (TICs) may be generated [20] and give rise to large 
GHRLOS transcripts. Because TICs must contain a first exon of the upstream gene 
[20], we employed primers in exon 2 (immediately after the start codon) of TATDN2 
and exon 1 of GHRLOS (which was also the sequence of our Northern riboprobe). 
Using nested RT-PCR (on cDNA reverse transcribed using oligo(dT) primers), we 
isolated a 2831 bp TATDN2-GHRLOS amplicon from the thymus 
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[GenBank:EU789553] (Fig. 4). This transcript has canonical splice donor and 
acceptor sites (GT/AG) and splices into the expected acceptor site of the 106 bp exon 
1. This variant harbour significant open reading frames corresponding to the 
TATDN2 protein, but contains alternative exons and a premature termination codon 
more than 50 bp upstream of the final coding exon 7 of TATDN2 (Fig. 4). This is 
likely to result in degradation of the mRNA by nonsense-mediated RNA decay 
(NMD), a surveillance mechanism that detects and degrades mRNA that may encode 
truncated proteins with dominant-negative or deleterious gain-of-function activities 
[21].  
 
We have identified several novel GHRLOS transcripts. This includes overlapping 
GHRLOS transcripts initiating in the TATDN2 3’ UTR and putative transcription-
induced chimaeras of TATDN2 and GHRLOS. These findings extend the previously 
reported length of GHRLOS by ~37 kb. We propose that GHRLOS harbour several 
promoters with start sites in exon 1 (of GHRLOS), and in the 3’ UTR and the first 
exon of TATDN2. 
 
Results of in silico analysis indicate that GHRLOS is a non-coding RNA gene 
Sequence analysis of GHRLOS (excluding the putative TATDN2-GHRLOS 
transcription-induced chimaeras that are likely to result in nonsense mediated decay) 
reveals that GHRLOS transcripts do not harbour protein coding potential, but rather 
have several features of non-coding RNA genes. GMAP analysis showed that 
GHRLOS spans approximately 44 kb on 3p25.3 (data not shown). The Mulan 
sequence conservation profile for the human and putative vertebrate GHRLOS 
orthologues indicated that most GHRLOS exons (I, II, III, 2, 3) are not highly 
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conserved compared to the putative mouse and rat orthologues (Fig. 5). The 106 bp 
exon 1 (which spans exon 4 of the ghrelin gene) and approximately 90 bp of the 1.4 
kb exon 4 (which spans exon -1 of the ghrelin gene) are conserved, however [8]. RT-
PCR experiments revealed no evidence for antisense transcription from exon I to exon 
1 (of GHRLOS) in the mouse (data not shown), suggesting that ghrelin antisense 
transcription (at these specific locations) may not be conserved. Furthermore, there is 
very low sequence similarity between the chicken, frog, opossum and human 
GHRLOS sequences (Fig. 5). Interestingly, exons II, 2 and 3 appear to be highly 
conserved between human and dog [Additional File 5], with 70—75% homology for 
exons 2 and 3. However, no significant open reading frames (ORFs) are conserved 
between dog and human GHRLOS sequence (data not shown). Taken together, this 
suggests that GHRLOS has evolved rapidly and may be unique to primates. 
 
Our study suggests that GHRLOS is a non-coding RNA. In silico translation revealed 
that the heterogeneous GHRLOS RNAs contain multiple stop codons, resulting in lack 
of extensive reading frames, and the putative ORFs do not span conserved regions 
(data not shown). Moreover, no significant sequence similarity to any known proteins 
was observed (data not shown). Finally, screening of GHRLOS sequence against a 
reference collection of repeats (RepbasE) using CENSOR [22] identified a 203 bp 
overlap of exon 4 with the extinct 224 bp MIR3 SINE element, which is present in all 
vertebrates [23] (Fig. 5). Interestingly, the presence of repeat elements in exons of 
non-coding RNAs has been reported previously [24-27] 
 
The GHRLOS terminal exon 4 and a putative SEC13 exon overlap in an 
antisense manner 
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We have discovered that exon 4 of GHRLOS is also on the opposite strand of a novel 
terminal exon of the neighbouring SEC13 gene in a tail-to-tail, 3’ to 3’, fashion (Fig. 
6A) [Additional File 6]. SEC13 plays an important role in protein transport and is a 
component of the COPII complex [28] [29]. BLAST analysis identified a brain 
tumour EST [GenBank:BF931280] [30], which contains exon 7 and 8 of SEC13, as 
well as 206 bp sequence corresponding to a novel exon 9b of SEC13 10.7 kb upstream 
of exon 8. We verified the expression of this EST by RT-PCR (using cDNAs reverse 
transcribed with oligo(dT) primers) (Fig. 6B) and by sequencing 
[GenBank:EU789555]. We have named this SEC13 variant, SEC13-tentative (SEC13-
T). SEC13-T may encode a 372 amino acid protein. The first 285 amino acids are 
identical to SEC13, while the normal C-terminal 37 amino acids have been replaced 
by 87 amino acids encoded by the alternative terminal exon 9b (Fig. 6C and D). The 
putative C-terminal-coding exon of the SEC13-T isoform appears to be conserved 
only in primates (data not shown). Therefore SEC13-T alternative splicing is likely to 
be human-specific or primate-specific.  
 
GHRLOS is expressed in many tissues and cell lines and the level of 
expression shows great variability 
RT-PCR analysis (with primers spanning GHRLOS terminal exons) and Northern 
blotting (which is only suitable for high copy number transcripts) demonstrated that 
the size of GHRLOS transcripts is highly variable, resulting in significant transcript 
heterogeneity. We, therefore, employed a quantitative, real-time RT-PCR approach in 
order to more precisely gauge the expression of GHRLOS in a range of tissues and 
cell lines. As the number of alternatively spliced GHRLOS transcripts makes it 
impossible to generate real-time RT-PCR primers that are unique to each splice 
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variant (data not shown), a strand-specific quantitative RT-PCR assay with primers in 
exon 4 (which is common to all GHRLOS variants) was designed to detect total 
GHRLOS RNA expression (Fig. 7A).  
 
The level of total GHRLOS transcript expression varied greatly in different human 
tissues, with high levels in the thymus, testis, foetal brain, uterus, cerebellum, ovary, 
thyroid, and whole brain. Very low levels of total GHRLOS RNA expression were 
detected in the stomach, foetal liver and pancreas (Fig. 7B). In the thymus the level of 
expression was approximately 133 fold higher than in the stomach (P<0.01) and 110-
fold higher than in the foetal liver (P<0.01). Furthermore, the level of expression in 
the adult liver was 9-fold higher than in the foetal liver (P<0.05), indicating 
differential expression according to developmental stage in this tissue. The level of 
GHRLOS in the foetal brain was two-fold higher than the adult brain, but this was not 
statistically significant (P>0.05). 
 
Expression of GHRLOS in a number of continuous cell lines was also examined using 
real-time RT-PCR (Fig. 7C). Levels of GHRLOS expression in the U-937 (Non-
Hodgkin’s lymphoma) and SW1353 (chondrosarcoma) cell lines were similar to the 
cerebellum, uterus, foetal brain, testis and thymus. High levels of expression were 
observed in the HEK293 human embryonic kidney cell line and in the CaCo-2 (colon 
adenocarcinoma), SAOS-2 (osteosarcoma), U-87 MG and U251-MG (glioblastoma), 
OVCAR-3 (ovarian adenocarcinoma) and Hep G2 (hepatocarcinoma) cancer cell 
lines. It is interesting to note that multiple Hep G2 CAGE tags have been identified in 
the exon I region of GHRLOS (see [Additional File 4]). GHRLOS RNA appears to be 
significantly upregulated in the Hep G2 cell line compared to adult and foetal liver 
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(P<0.05) (Fig. 7B and C). This observation could indicate that GHRLOS may be a 
specific target in the development of liver and other cancers.  
 
Comparison of total GHRLOS and total GHRL expression  
We examined the expression levels of the GHRL-GHRLOS cis-natural antisense 
transcript (cis-NAT) pair via quantitative real-time RT-PCR assays detecting total 
transcription from the ghrelin gene (GHRL). As expected [31], the highest level of 
GHRL expression was found in the stomach (data not shown), followed by the testis 
and pancreas (Fig. 8). When comparing total ghrelin and GHRLOS RNA expression 
in the stomach, GHRL was expressed at 2300 fold higher levels than GHRLOS, with 
GHRLOS expression almost undetectable (P<0.001). The levels of GHRLOS 
expression were higher than GHRL in the thymus, whole brain, the SW1353 
chondrosarcoma cell line, uterus and prostate. However, total GHRL RNA levels were 
higher than GHRLOS in the pancreas and the OVCAR-3 ovarian cancer cell line. 
 
Discussion 
Our study demonstrates that GHRLOS gives rise to long, extensively spliced, mRNA-
like, 5’ capped and 3’ polyadenylated transcripts suggesting that they are genuine 
products of RNA polymerase II mediated transcription [32]. We have shown that the 
GHRLOS gene gives rise to transcripts 1.0 to 5.5 kb in size and has many broadly 
distributed transcription starts sites (TSSs) (Fig. 9). This includes several TSSs in 
exon 1, TSSs overlapping the 3’ UTR of TATDN2 and evidence of transcription 
induced chimaeras employing TSSs in the first exon of TATDN2. The ghrelin locus, 
therefore, gives rise to many antisense transcripts that are currently annotated as a 
single gene, GHRLOS. A well-described example of such complex architecture is the 
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imprinted murine Gnas locus, which gives rise to multiple coding and non-coding 
sense and antisense transcription units [33]. 
 
First reported in 1987 [34] and originally thought to be a rarity, it has recently been 
established that promoters in 3’ untranslated regions (3’ UTRs) are not uncommon 
and may be independently transcribed and regulated from their upstream “host gene” 
[35]. The ENCODE (ENCyclopedia Of DNA Elements) consortium has recently 
demonstrated that two-thirds of the loci in their dataset contain new putative first 
exons, which frequently overlap upstream genes  [36]. However, it is currently not 
known how promoters that overlap 3’ UTRs are regulated and coordinated [37]. We 
have demonstrated GHRLOS transcription start sites in the 3’ UTR of TATDN2 via 
RLM-RACE. The sequence upstream of exon I of GHRLOS contains no apparent 
TATA boxes (data not shown), indicating that GHRLOS has a broad type promoter, 
with many potential transcription start sites in the 2.1 kb 3’ UTR of TATDN2. This 
may allow the transcription of numerous tissue-specific and developmental stage-
specific transcripts [19]. In addition, multiple CAGE tags are present in the 3’ UTR of 
TATDN2, indicating that GHRLOS transcripts initiate in this region.  
 
Interestingly, we also report the joining of exons of the neighbouring genes TATDN2 
and GHRLOS. Similar chimaeric transcripts (not caused by chromosomal 
translocation) have been reported in lower eukaryotes [38, 39], but were until recently 
assumed to be relatively rare in mammals [20, 40-43]. It is not known how chimaeric 
transcripts arise, but transcriptional read-through, followed by canonical cis-splicing 
is the most likely mechanism [40]. Alternatively, chimaeric transcripts could arise 
through trans-splicing, but the existence of this mechanism has not been well-
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established in mammals [44]. We, therefore, suggest that the chimaeric TATDN2-
GHRLOS transcripts probably result from a single pre-mRNA, creating transcription-
induced chimaeras (TICs) which are spliced in cis [40]. The TATDN2-GHRLOS TIC 
which was identified in the normal thymus harbours premature stop codons (PTCs) 
and this is likely to result in nonsense-mediated decay (NMD). NMD is an RNA 
surveillance mechanism (present in eukaryotes) which targets mRNA with premature 
stop codons that, if translated, encode truncated proteins with dominant-negative or 
deleterious gain-of function activities [21]. Whilst we are not aware of any studies of 
the translated product of TATDN2 (TatD DNase domain containing 2), TatD is a 
cytoplasmic protein that harbours magnesium-dependent DNase activity in E.coli 
[45]. Proteins with a TatD domain, therefore, belong to the large superfamily of 
metalloenzymes. This suggests that the chimaeric transcripts may play a role in auto-
regulation of the TATDN2 protein product, which we hypothesise is likely to be a 
DNase associated with apoptosis. We speculate that TATDN2-GHRLOS chimaeras 
may be used to tightly regulate the programmed cell death of T-cells by 
downregulating the translation of the putative DNase TATDN2. Hillman and 
colleagues have termed this system of auto-regulation, where alternative splicing 
results in mRNA isoforms that are not translated, regulated unproductive splicing and 
translation (RUST) [46]. Interestingly, it has very recently been reported that 
transcripts of the tumour suppressor protein E-cadherin that result in non-sense 
mediated decay are upregulated in gastric cancer, suggesting that NMD may also 
promote disease [47]. 
  
We previously reported that GHRLOS completely overlaps the ghrelin (GHRL) gene 
[8]. Here we also show that the 3’ terminal exon 4 of GHRLOS is present on the 
 - 17 - 
opposite (antisense) strand to a novel, 3’ terminal SEC13 exon (Fig. 8). SEC13 is a 
protein that forms a part of the coat protein complex II (COPII) [28]. COPII proteins 
are required for the trafficking of nascent proteins from the endoplasmic reticulum 
(ER) to the Golgi apparatus. It also plays a role in the selection and concentration of 
cargo proteins for transport [29]. SEC13 [28], therefore, has a core endocrine 
function.  GHRLOS overlaps a novel SEC13 variant, SEC13-tentative (SEC13-T). 
SEC13-T may encode a 372 amino acid protein with a unique C-terminus. Future 
studies are required to confirm the presence of full-length transcripts and to elucidate 
the functional role of SEC13-T protein. We suggest that transcription of SEC13-T 
may have implications for COPII function in health and disease states. As GHRLOS 
overlaps the terminal exons of both GHRL and SEC13-T, the GHRLOS natural 
antisense transcripts may regulate one or both of these genes.  
  
GHRLOS, a candidate non-coding RNA 
Non-coding RNAs are frequently not conserved between species, suggesting that they 
are either biological noise (non-functional transcription), or that they have species 
specific-functions. Species-specific non-coding transcripts have been observed and 
there is strong evidence that non-coding transcripts are functionally significant [48-
52]. Interestingly it has recently been observed, using in silico analysis, that even 
between closely related Drosophila species non-coding RNAs are not conserved [53]. 
While the number of protein coding genes in distant eukaryotes (such as worms, mice, 
and humans) is approximately equal, the relative amount of non-coding DNA 
increases in proportion to eukaryotic complexity [54, 55]. Mattick and colleagues 
explain this paradox by hypothesising that non-coding RNAs have evolved to enable 
the emergence of organisms with increasingly complex higher levels functions [55, 
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56]. Our in silico analysis suggests that GHRLOS exons show very low sequence 
conservation in vertebrate species. Furthermore, exon 4 of GHRLOS contains a 
transposable element, a feature observed in many non-coding RNAs [25-27]. 
 
Our bioinformatic studies indicate that GHRLOS does not encode a protein and, 
therefore, is a non-coding RNA. Taking into account the full-length sequence of 
GHRLOS, the length of the open reading frames is very short. Moreover, GHRLOS 
RNAs are numerous (due to extensive splicing), contain a large number of stop 
codons and there is little nucleotide and putative amino acid conservation between 
vertebrates, making it less likely that this gene encodes proteins. Although it has been 
suggested that many small peptides may be translated [57], the majority of small 
peptides are processed from larger precursor proteins, as is ghrelin itself which is 
processed from preproghrelin. Therefore, while it cannot be excluded that GHRLOS 
encodes short ORFs (that are not conserved in the mouse) it appears unlikely that 
GHRLOS encodes biologically active peptides. 
  
We examined the GHRLOS expression profile to strengthen the hypothesis that it is a 
candidate non-coding RNA. It has been demonstrated that mammalian long non-
coding RNAs are expressed in a tissue-specific manner, indicating that they are 
biologically significant [50, 58-61]. In both humans and mice, the major tissues of 
non-coding expression are the complex organs; the brain, testis, and thymus [50, 61]. 
This also holds true in Drosophila, where the majority of the candidate non-coding 
RNAs are expressed in the central nervous system [53]. Indeed, non-coding RNAs are 
emerging as important regulators of complex systems, such as the central nervous 
system (brain) and intricate processes, including spermatogenesis in the testis [62-65]. 
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We demonstrated high levels of GHRLOS in the thymus, brain, testis, uterus, ovary 
and thymus, while the expression levels in the stomach, where GHRL is highly 
expressed [1], were almost undetectable. Our data demonstrate that GHRLOS is 
predominantly expressed in a limited number of tissues and cell types, suggesting that 
these transcripts have physiological functions in distinct cell types and tissues. 
Moreover, real-time RT-PCR showed extremely low levels of GHRLOS in the foetal 
and adult liver and high levels in the Hep G2 hepatocarcinoma cell line, suggesting 
that GHRLOS expression may be altered in liver cancer. Indeed, it has recently been 
reported that non-coding RNA expression is frequently altered in cancer [58, 66]. This 
indicates that non-coding RNAs may have specific functions in normal cells. Much 
like protein-coding transcripts, ncRNAs may act as tumour suppressors, or be 
upregulated in cancer and act as oncogenes. An examination of GHRLOS expression 
in cancer would, therefore, be of great interest.  
 
Here we have characterised the structure and organisation of GHRLOS, a ghrelin 
antisense gene, suggesting that GHRLOS has multiple first exons. Therefore, it is 
possible that GHRLOS could be a part of very large, continuous ncRNA species in the 
3p25 chromosomal region and beyond. In the absence of hallmarks, such as large 
open reading frames, mapping complex non-coding RNA genes remains a complex 
task. For example, two RNAs in the FMR1 locus, the cis-NAT ASFMR1 [67] and the 
non-coding RNA gene FMR4 (found just upstream of FMR1 [51]) may be one 
continuous RNA isoform [51]. 
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What is the function of GHRLOS? 
It is currently difficult and costly to determine the mechanism of function of long non-
coding RNAs. The roles of non-coding RNAs are likely to be diverse, and there is 
strong evidence that they play a role in regulating important pathways. Many ncRNAs 
are expressed during development, neural differentiation, during macrophage 
activation and in cancer, indicating that they have key functions in these processes 
[12, 63, 68]. Non-coding RNAs have been found to play a role in the silencing of 
overlapping genes in cis [69], in the silencing of distant chromosome regions in trans 
[70], in nuclear trafficking [71], apoptosis [51, 72], promoter repression [73], and can 
act as tumour suppressors [74]. Moreover, ncRNAs are emerging as markers for 
complex human disease, including lung cancer [75], heart disease [76], and a range of 
other pathologies [68, 77]. GHRLOS may also serve as a host gene for snoRNA (small 
nucleolar RNAs) genes [78] or GHRLOS RNA transcripts may be precursors for short 
RNAs, such as micoRNAs [77], endogenous siRNAs [79, 80], piRNAs [81] and other 
novel, short non-coding RNA species [82, 83].  
 
Although the understanding of natural antisense transcripts (NATs) remains in its 
infancy, they have been associated with a range of regulatory mechanisms that are not 
necessarily mutually exclusive. This includes transcriptional interference, RNA 
masking and dsRNA mediated gene-silencing via direct interaction between the sense 
and antisense transcripts [9, 84, 85].  
 
While it is difficult to predict GHRLOS function, the fact that all spliced GHRLOS 
variants share exon 1, which overlaps the 3’ untranslated exon 4 of GHRL is striking. 
Our findings suggest that GHRLOS functions as a non-coding RNA. There are a few 
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examples that suggest that antisense transcripts are important in the regulation of 
endocrine hormone receptors, including a thyroid hormone receptor [86, 87], and the 
luteinising hormone/choriogonadotropin receptor [88] gene and in the regulation of 
growth factors [89]. Interestingly, it has been recently suggested that the invertebrate 
(insect) polypeptide hormone allatostatin may be regulated by cis-NATs [90]. To 
date, however the physiological and pathophysiological roles of natural 
sense/antisense pairs have not been elucidated for any vertebrate endocrine hormone. 
Further studies are necessary to reveal the function and molecular mechanisms 
regulating the candidate non-coding RNA gene GHRLOS. 
 
Conclusions  
In the present study, we have characterised GHRLOS, which gives rise to endogenous 
ghrelin natural antisense transcripts. GHRLOS exhibits features which are common to 
many non-coding RNA genes, including extensive splicing, lack of significant and 
conserved open reading frames, differential expression and lack of conservation in 
vertebrates. Our data also reveal that GHRLOS contains multiple first exons and that it 
overlaps both GHRL and a novel SEC13 exon in the antisense direction, suggesting 
that GHRLOS may have a role in regulating these genes. Moreover, we report 
TATDN2-GHRLOS chimaeras that may function to regulate the translation of the 
putative DNase TATDN2. Additional studies are underway to elucidate the functions 
of GHRLOS and to investigate, in particular, its overlapping genomic arrangement 
with the ghrelin gene. These studies may provide a new, physiologically relevant 
model system for investigating the roles of antisense gene and non-coding RNA 
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regulation and the mechanisms involved, as well as establishing whether GHRLOS 
RNAs may be useful markers for diagnosis and prognosis of complex disease. 
 
Methods 
Bioinformatics  
 
Multiple sequence alignments were generated using the MUltiple sequence Local 
AligNment and conservation visualization tool (Mulan) [91]. Human [UCSC hg18], 
chicken [UCSC galGal3], frog [UCSC xenTro2], opossum [UCSC monDom4], 
mouse [UCSC mm9], rat [UCSC rn4], dog [UCSC canFam2], rhesus macaque 
[UCSC rheMac2], and chimpanzee [UCSC PanTro2] genomic sequences were 
obtained via the Evolutionary Conserved Regions (ECRs) Browser [92] and 
forwarded to Mulan to generate a full local alignment of the GHRLOS locus. 
GHRLOS was annotated based on the exons sequenced in this study. 
 
To identify putative antisense exons and transcripts, we examined the publicly 
available Affymetrix Human Exon 1.0 ST Array tissue panel dataset consisting of 11 
tissues (breast, cerebellum, heart, kidney, liver, muscle, pancreas, prostate, spleen, 
testes, and thyroid) using the Affymetrix All Exon track in the UCSC Genome 
Browser [93] and the Integrated Genome Browser (IGB) from Affymetrix [94].  
 
To locate transcription start sites in the putative first exons of GHRLOS, CAGE (Cap 
Analysis of Gene Expression) tags (deposited by the RIKEN consortium and its 
collaborators) were obtained via the Genome Network Platform Viewer [95]. We then 
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recovered the RNA library information for each CAGE tag starting site. Briefly, each 
CAGE tag was individually queried against the 1.4 GB CAGE tag sequencing file, 
(release date 13.11.2006) available on the Genome Network Platform website using 
the UNIX grep command [96]. 
 
The exon-intron-structure of ESTs and mRNA entries identified from BLAST 
searches, as well as sequenced PCR amplicons obtained in this study, were analysed 
against the human genome (NCBI release 35) using GMAP [14]. Presence of open 
reading frames was analysed by NCBI ORF Finder [97], Fickett’s TestCode [98, 99] 
and ESTScan2 [100, 101]. The presence of transposable elements in GHRLOS 
sequence was examined using CENSOR v4.2.8 [22]. Protein domain analysis was 
performed using the SMART database [102]. 
 
Cell culture and RNA extraction 
The following cell lines (originally obtained from the American Type Culture 
Collection/ATCC, Rockville, MD unless specified) were cultured in their 
recommended media: Prostate and/or prostate cancer derived cell lines DU145 
(ATCC HTB-81), RWPE-1 (ATCC CRL-11609), RWPE-2 (ATCC CRL-11610), 
LNCaP (ATCC CRL-1740), 22Rv1 (ATCC CRL-2505) and PC3 (ATCC CRL-1435), 
HEK293 human embryonic kidney (ATCC CRL-1573), SAOS-2 osteosarcoma 
(ATCC HTB-85), Hep G2 hepatocarcinoma (ATCC HB-8065), U-87 MG and U-251 
MG glioblastoma (ATCC HTB-14 and JCRB Cell Bank # IFO50288, respectively), 
CaCo-2 colorectal adenocarcinoma (ATCC HTB-37), SW1353 chondrosarcoma 
(ATCC HTB-94), and OVCAR-3 ovarian cancer (ATCC HTB-161). All cells were 
grown in T80 or T175 flasks (Nagle Nunc International, Roskilde, Denmark) in 95% 
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CO2 in a Sanyo incubator at 37 °C. Total RNA was harvested from cultured cells at 
70% confluence using TRIzol reagent (Invitrogen, Carlsbad, CA) according to the 
manufacturer’s instructions.  
 
Human RNA samples 
Tissue Total RNA was obtained from the stomach, prostate (FirstChoice, Ambion, 
Austin, TX), foetal liver, adrenal gland, liver, trachea, salivary gland, spinal cord, 
skeletal muscle, lung, placenta, bone marrow, kidney, heart, whole brain, thyroid, 
cerebellum, uterus, foetal brain, testis, thymus (Human total RNA Master Panel II, 
Clontech, Mountain View, CA) and pancreas (Clontech). 
 
5’ and 3’ RACE mapping of GHRLOS transcripts 
To further characterise the 5’ end of the putative ghrelin antisense RNAs, 5' RACE 
was undertaken using FirstChoice RLM-RACE-Ready human stomach cDNA 
(Ambion) according to the manufacturer’s instructions. The first round PCR was 
performed with an adapter-specific sense primer (5’adapter-out-F, Table 1) and an 
exon 2-specific antisense primer (5’OS-out-R in Table 1). PCR product (1 µl) was 
used in a secondary, nested PCR with a gene specific primer in exon 2 (5’adapter-in-F 
and 5’OS-in-R, Table 1). PCRs were performed in a total reaction volume of 50 µl 
using 1 U of Platinum Taq Polymerase High Fidelity (Invitrogen) according to the 
manufacturer’s instructions.  
 
For GHRLOS 3’ RACE, human stomach and PC3 prostate cancer cell line total RNA 
was reverse transcribed using Transcriptor reverse transcriptase (Roche Applied 
Science Applied Science, Penzberg, Germany) and 10 µM adapter primer (3′-RACE-
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adapter, Table 1) from the FirstChoice RLM-RACE Kit (Ambion). 3’ RACE was 
performed with 2 µl of this cDNA. Two 3’ RACE reactions were performed – one 
combined an exon 4 GHRLOS-specific forward primer and an adapter-specific reverse 
primer (3’4F and 3’2OR, Table 1), and the other used an adapter-specific reverse 
primer and an exon 2-specific forward primer 3’2OR/F, Table 1). PCR products were 
then diluted and used in a secondary, nested PCR with a gene-specific forward and a 
reverse adapter primer (3’2IF/R, Table 1). PCR products were purified using a High 
Pure PCR purification kit (Roche Applied Science), cloned into pCR-XL-TOPO 
(Invitrogen) or pGEM-T Easy (Promega, Madison, WI), transformed into DH5α 
chemical competent cells (Invitrogen) and sequenced at the Australian Genome 
Research Facility (AGRF, Brisbane, Australia) using BigDye III (Applied 
Biosystems, AB, Foster City, CA).  
 
Determination of GHRLOS transcription start and polyadenylation sites by 
Rolling Circle Amplification Rapid Amplification of cDNA Ends (RCA-RACE)  
To simultaneously obtain the 5’ and 3’ ends of GHRLOS transcripts, we employed 
Rolling Circle Amplification-RACE (Rapid Amplification of cDNA Ends [103], an 
improved inverse PCR approach. Briefly, 3 µg stomach, prostate, RWPE-1 cell line 
and PC3 prostate cancer cell line total RNA were reverse transcribed using 10 U of 
Transcriptor reverse transcriptase (Roche Applied Science) and 100 µM HPLC-
purified 5’-end phosphorylated oligo d(T)-adapter primer (Phospo-dT, Table 1) 
(Proligo, Boulder, CO) according to the manufacturer’s instructions. The single-
stranded cDNA was purified using a High Pure PCR purification kit (Roche Applied 
Science) and eluted in 50 µl elution buffer (10 mM Tris-HCl, pH 8.5). Next, 25 µl 
purified linear cDNA was circularised using 100 U of CircLigase (EPICENTRE 
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Biotechnologies, Madison, WI) and purified as before. After self-ligation, 15 µl 
circular cDNA was added to a rolling circle amplification reaction with 10 U of φ29 
DNA polymerase (NEB) and 10 µM HPLC-purified random hexamer primers with 
two phosphothioate linkages on their 3’ends (Pthioate-hex, Table 1) (Proligo). 
Following a 21h incubation at 30 °C in a waterbath, RCA-products were subjected to 
two rounds of inverse PCR with 1 U of Platinum Taq HIFI polymerase (Invitrogen), 
as per manufacturer’s instructions. PCRs were performed in a reaction volume of 50 
µl using a PTC-200 thermocycler (MJ Research, Waltham, MA). For the first round 
amplification, the RCA reaction was diluted 1/100 in water, and 1 µl used in an outer 
PCR with a forward primer at the start of exon 4 and a reverse primer in exon I 
(IPCR-out-F and IPCR-ALL-R, Table 1). After 35 cycles at a 60 °C annealing 
temperature, the outer PCR product was diluted 100 times in water and 1 µl was used 
in a hemi-nested PCR of 20 cycles, with annealing at 60 °C (IPCR-in-F and IPCR-
ALL-R, Table 1). Amplification products were eluted from agarose gels in 50 µl 
water overnight, reamplified, cloned into pCR-XL-TOPO (Invitrogen), transformed 
into One Shot MAX Efficiency DH5α-T1R chemically competent cells (Invitrogen) 
and sequenced at the Australian Genome Research Facility (AGRF, Brisbane, 
Australia). 
 
Northern blot hybridisation 
Initially, a cRNA probe spanning exon I, II, 1 and 2 of GHRLOS was employed. 
Briefly, a 5’ RACE clone in pGEM-T Easy was linearised with SalI restriction 
enzyme and a cRNA probe was synthesised using T7 RNA polymerase and a 
digoxigenin (DIG) RNA labelling kit (Roche Applied Science). Probe concentration 
was estimated by dot blot comparison with digoxigenin-labelled standards. 500 ng 
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stomach poly(A)+ RNA (FirstChoice, Ambion) was separated on a 1.2% 
formaldehyde gel and blotted, as described previously [104]. Samples were 
electrophoresed with 50 ng RNA Molecular Weight Marker II (Roche Applied 
Science). The blot was hybridised to 50 ng/mL DIG-labelled cRNA probe overnight. 
Prehybridisation and hybridisation was performed with DIG-Easy Hyb (Roche 
Applied Science) at 65 °C. The membranes were washed twice for 5 min at room 
temperature with 1 × Saline-Sodium Citrate (SSC), 0.1% sodium dodecyl sulfate 
(SDS) and then washed three times for 10 min at 65°C with 0.1 × SSC, 0.1% SDS. 
The membrane was then reacted with an alkaline phosphatase (AP)-conjugated anti-
DIG antibody (Roche Applied Science). AP activity was detected using a 
chemiluminescence method using CDP-Star (Roche Applied Science). 
 
A second cRNA probe, which spanned exon 1 (which is common to all known 
GHRLOS mRNA isoforms) was synthesised from 100 ng human stomach genomic 
DNA (BioChain, Hayward, CA) using the PCR method [103] (Ex1-cRNA-F/R, Table 
1). The PCR product was purified using a High Pure PCR Product Purification Kit 
(Roche Applied Science) and the DIG-labelled cRNA probe synthesised and 
quantified as detailed above. A multi-tissue membrane containing poly(A)+ RNA 
from 12 human tissues (brain, duodenum, oesophagus, pancreas, PBL/leukocytes, 
prostate, salivary gland, testis, thymus, thyroid, urinary bladder and uterus) was 
purchased from OriGene (Rockville, MD). Prehybridisation and hybridisation were 
performed as described above, except that ULTRAhyb Ultrasensitive Hybridization 
Buffer (Ambion) was used instead of DIG-Easy Hyb (Roche Applied Science). 
Equivalent loading between tissues on the blot was determined by rehybridising with 
20 ng/mL DIG-labelled β-actin cRNA probe (Roche Applied Science). 
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Isolation of alternatively spliced GHRLOS mRNAs via non-quantitative RT-PCR  
For non-quantitative RT-PCR analysis of GHRLOS splicing, RT-PCRs were 
performed with a forward primer in a region common to the 5’ terminal exon Ia/b and 
a reverse primer in the 3’ terminal exon 4 of GHRLOS (Ito4-F/R, Table 1). cDNA was 
synthesised in a final volume of 20 µl from 3 µg total RNA from tissues and cell lines 
using 10 U of Transcriptor reverse transcriptase (Roche Applied Science), 20 U of 
RNasin Plus RNase Inhibitor (Promega) and a 3’ RACE adapter primer (3′-RACE-
adapter, Table 1) at 55 °C according to the manufacturer’s instructions. PCR 
amplicons from the stomach, prostate, foetal brain, heart, thymus, testis, and pancreas 
were purified, sub-cloned and sequenced as described above. 
 
Long-range RT-PCR to detect putative chimaeric TATDN2-GHRLOS transcripts 
To detect long, chimaeric transcripts, we employed RT-PCR with a forward primer in 
exon 2 of TATDN2 (ChiOut-F, Table 1) and a reverse primer in exon 1 of GHRLOS 
(ChiOut-R, Table 1). PCR was carried out with 1 U of Platinum Taq HIFI polymerase 
(Invitrogen) as per manufacturer’s instructions, extending at 68 °C for 2.5 minutes per 
cycle. cDNA was synthesised as above in a final volume of 20 µl from 2 µg total 
RNA, from the Hep G2 hepatocarcinoma cell line, CaCo-2 colorectal adenocarcinoma 
cell line, OVCAR-3 ovarian cancer cell line, and from a range of normal tissues 
(testis, prostate, pancreas, thymus, and foetal brain). RT-PCR products were sub-
cloned and sequenced as described above. 
 
CAGE-aided cDNA primer walking 
To determine if the identified upstream CAGE tag starting sites transcribe exons that 
belong to GHRLOS, we employed RT-PCR using a forward primer designed to the 
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region immediately after a CAGE cluster in the ~2 kb 3’ untranslated region of the 
adjacent gene TATDN2 (TSS ID T03F009D1927) and a reverse primer in exon 1, an 
exon which is common to all known GHRLOS variants (F_CAGE and R_CAGEout in 
Table 1, respectively). cDNA was synthesised in a final volume of 20 µl from 2 µg 
total RNA, from the Hep G2 hepatocarcinoma cell line and the thymus and foetal 
brain, using 10 units Transcriptor reverse transcriptase (Roche Applied Science), 20 U 
of RNasin Plus RNase Inhibitor (Promega) and oligo(dT)18 primers (Proligo) 
according to the manufacturer's instructions. The cDNAs were subjected to 35 cycles 
of PCR with a two-minute extension time per cycle, and then diluted 1/100 in water 
and subjected to a hemi-nested 30-cycle PCR with a nested primer in exon 1 
(R_CAGEin, Table 1). PCRs were performed in a total reaction volume of 50 µl using 
10 U of Platinum Taq Polymerase High Fidelity (Invitrogen) according to the 
manufacturer's instructions. Entire PCR products were purified using the High Pure 
PCR Product Purification Kit (Roche Applied Science), subcloned into pCR-XL-
TOPO (Invitrogen) and transformed into One Shot MAX Efficiency DH5α-T1R 
chemical competent cells (Invitrogen). Insert-positive, purified clones were sequenced 
by the Australian Genome Research Facility (AGRF, Brisbane, Australia) using the 
AB PRISM BigDye Terminator Cycle Sequencing Kit v3.1 protocol (AB).  
 
Identification of novel SEC13 exon 
To verify the presence of a novel SEC13 exon identified in a brain tumour EST 
[GenBank:BF931280], cDNAs reverse transcribed with an oligo(dT) primer (as 
described above) were challenged by RT-PCR with primers in exon 8 of SEC13 and a 
reverse primer in the novel exon (231-F/R, Table 1, respectively). 
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Strand-specific, quantitative real-time RT-PCR 
To allow strand-specific and RNA-specific amplification [103, 105, 106] of GHRLOS 
transcripts, reverse transcription was performed using a gene-specific primer in exon 
4 with a linker (LK) [107] sequence attached to the 5’ end of the primer (GHRLOS-
Real-RT-LK, Table 1). cDNA was generated from 1 µg total RNA using 40 U of 
AMV reverse transcriptase (Roche Applied Science) at 42 °C, according to the 
manufacturer’s instructions. The strand-specific, real-time RT-PCR was performed 
with an exon 4 specific forward primer, a reverse primer with the LK sequence only 
(GHRLOS-Real-F and LK, Table 1) and a TaqMan probe (Ex4-TaqMan, Table 1). To 
detect sense GHRL transcripts, we employed a strand-specific RT-PCR approach, 
with a reverse transcription primer spanning the 3’ terminal exon  4 of the ghrelin 
gene (GHRLex4_RT_LK, Table 1) followed by PCR with an exon 4 specific forward 
primer (GHRLex4_F, Table 1) and a linker-specific reverse primer. (LK, Table 1). 
The relative quantification of GHRLOS and GHRL transcripts was estimated by direct 
normalisation to the threshold cycle (CT) of the housekeeping gene, 18S ribosomal 
RNA (18S-Real-F/R, Table 1). 18S PCRs were used to normalise real-time data. As 
reported for GAPDH [108], 18S RNAs self-primes efficiently in reverse transcription 
reactions without the addition of random or gene-specific primers. All primers were 
designed using the Primer Express version 2.0 software (AB).  
 
PCRs were performed in a total reaction volume of 20 µl using Platinum Quantitative 
PCR SuperMix-UDG w/ROX (Invitrogen) for GHRLOS, while GHRL and the 
housekeeping gene 18S ribosomal RNA were amplified using 2 x SYBR green master 
mix (AB). Controls included the use of cDNA, which was reverse transcribed using 
random hexamers as primers, as well as the reverse transcription of RNA in the 
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absence of primer. Real-time RT-PCR was performed using the AB 7000 sequence 
detection system (AB) and data analysed using the absolute standard curve method 
(User Bulletin #2, AB) to determine expression levels in a range of tissues and cell 
lines. Briefly, we calculated values from duplicate reactions for each sample from 
standards, which were constructed from PCR products. Statistical significance was 
determined using the Student’s t-test and, where applicable, one-way analysis of 
variance (ANOVA) with Tukey post-hoc analysis. P-values of <0.05 were considered 
to be statistically significant. Data are represented as mean ± standard deviation 
(S.D.). 
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Figure legends 
 
 
Figure 1 – Mapping of GHRLOS transcript 5’ and 3’ ends 
Relative positions of the 5‘ and 3’ ends of GHRLOS transcripts were derived from 
RACE, inverse PCR and cDNA primer walking RT-PCR experiments, as well as from 
publically available data from EST databases, Affymetrix exon arrays and CAGE 
tags. TATDN2 exons are shown as white boxes, GHRLOS exons as black boxes, 
introns as horizontal lines. Size (bp) of selected exons are shown above each exon. All 
known 3’ ends of GHRLOS transcripts contain the same polyadenylation signal. 
Poly(A) tails are represented by AAAA. Cap-analysis gene expression (CAGE) tags 
are indicated by arrows, and CAGE-aided cDNA primer walking amplicons are 
displayed below the arrows. Not drawn to scale.  
 
Figure 2. Northern blot of poly(A)+ RNA from normal, human tissues with 
strand-specific, DIG-labelled riboprobe 
Northern blot of 2 µg poly(A)+ RNA from 12 normal tissues (OriGene) probed for 
exon 1, which is an exon common to all known GHRLOS mRNA isoforms (top 
panel). The position of the RNA size markers is indicated (RNA Millennium Markers, 
OriGene). A pound mark (#) indicates a putative 1.7-1.8 kb (approximately 2.0 kb 
with polyadenylation tail) full-length transcript in the prostate, as deduced from RLM-
RACE and RT-PCR experiments. Several other transcripts 1-5.5 kb in size could be 
seen. The same membrane was stripped and hybridized with a β-actin cRNA probe as 
a loading control (bottom panel).  
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Figure 3. Complex pattern of GHRLOS variant exon expression 
GHRLOS transcripts A to M were demonstrated by RT-PCR, while the 5’ end (exon 
I) and 3’ end (exon 4) were determined by RACE, inverse PCR and by examining 
publically available Affymetrix exon array data and expressed sequence tag (EST) 
data. Exons are represented as boxes, introns as horizontal lines and sizes (bp) are 
indicated below each exon. The size of exon 4a is listed as 1377-1388 and 
corresponds to a transcript which is polyadenylated 20-30 bp from the same 
polyadenylation signal (data not shown). Exon 4b harbours the same polyadenlation 
site, but is 5’ truncated (250 bp). GhrelinOS variants A to M have been deposited to 
GenBank: A-F, stomach [GenBank:EU789534, EU789535, EU789536, EU789537, 
EU789538, and EU789539]; G-H, prostate [GenBank:EU789540, and EU789541]; I, 
foetal brain [GenBank:EU789542]; J-M, heart [GenBank:EU789543, EU789544, 
EU789545, and EU789546]. 
 
Figure 4. Identification of a TATDN2-GHRLOS chimaeric transcript by nested 
RT-PCR 
(A)  Overview of the gene structures of TATDN2 (orange) and GHRLOS exons (blue). 
TATDN2 exon 8 contains first exons of GHRLOS and is therefore shown in orange 
and blue. Exons are represented as boxes, introns as horizontal lines and sizes (bp) are 
indicated below each exon. A TATDN2 CpG island is shown as a green box. The 
location of RT-PCR primers employed to detect chimaeras are shown below each 
exon as arrows. The reported 761 amino acid TATDN2 open reading frame (encoded 
by [GenBank:NM_014760]) is shown as a straight line (M=initiating methionine; 
*=stop codon). A chimaeric TATDN2-GHRLOS transcript, its open reading frame and 
locations of a premature stop codon (*) is shown. Not drawn to scale. (B) Ethidium 
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bromide stained agarose gel of nested RT-PCR product for the TATDN2-GHRLOS 
chimaera. Arrows indicates the amplicon schematically displayed in (A). M=1 kb 
DNA Ladder (NEB). 
 
Figure 5. Mulan sequence conservation profile for vertebrate GHRLOS loci 
The horizontal axis displays the input sequence from human (UCSC hg18), chicken 
[UCSC galGal3], frog [UCSC xenTro2], opossum [UCSC monDom4], mouse [UCSC 
mm9], rat [UCSC rn4], dog [UCSC canFam2], rhesus macaque [UCSC rheMac2], 
and chimpanzee [UCSC PanTro2] GHRLOS loci. Evolutionary conserved regions 
(ECRs, > 70% identity; ≥ 99 bp) are depicted as dark red bars above each pairwise 
alignment. Exons (blue), intergenic elements (red) and intron sequence (pink) are 
marked and the vertical axis shows the percent similarity of vertebrate GHRLOS 
orthologues to the human sequence. GHRLOS exon numbers are shown. A 
transposable element in exon 4 (MIR3#SINE/MIR) is shown above exon 4. 
 
Figure 6. GHRLOS overlaps a putative SEC13 isoform, SEC13-T, in an 
antisense manner 
(A) Diagrammatic representation of GHRLOS, SEC13, and a novel SEC13 isoform, 
named SEC13-tentative (SEC13T). SEC13-T contains a novel terminal exon 9, termed 
exon 9b, which overlaps exon 4 of GHRLOS in an antisense manner. In the figure, 
exon 9b of SEC13-T is dotted to indicate that its complete 3’ end has not been 
verified. Exons are represented as boxes and introns as horizontal lines. The locations 
of the primers employed to verify the SEC13T variant are displayed as arrows. SEC13 
and SEC13-T GenBank accession numbers are shown. (B) Ethidium bromide stained 
agarose gel showing the verification of a SEC13-T EST [GenBank:BF931280] 
transcription by RT-PCR in prostate (RWPE-1 and RWPE-2) and prostate cancer 
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derived cell lines (DU-145, PC3, LNCaP). NTC=no template control (water). M= 
DNA Molecular Weight Marker VI (Roche). Primer locations are depicted in (A). A 
231 PCR fragment was amplified and sequenced, confirming the EST. (C) RNA and 
amino acid sequence of exon 9b of SEC13-T. Additional downstream sequence 
corresponding to 18 in-frame codons and a stop codon is highlighted in green. (D) 
SEC13 and SEC13-T amino acid sequences. SEC13 encodes a 322 AA protein with 
six WD-40 repeats (also known as WD or beta-transducin repeats) are underlined. 
Amino acid sequence of SEC13 which is different to SEC13T is shown in blue. 
SEC13-T may encode a 372 AA protein: Its first 285 amino acids are identical to 
SEC13 and the normal C-terminal 37 amino acids have been replaced by 87 amino 
acids (shown in red) encoded by exon 9b. 
 
Figure 7. Strand-specific GHRLOS real-time RT-PCR  
(A) Strand-specific real-time RT-PCR approach to quantify GHRLOS expression. To 
select for RNA generated from the antisense strand, a linker sequence (LK) (not 
present in the genomic sequence of GHRLOS) is attached to a GHRLOS gene specific 
primer and employed in reverse transcription. The resulting cDNA is then combined 
in a real-time PCR, combining a gene-specific primer (GSP) and a primer containing 
the linker region from reverse transcription primer only. An internal TaqMan probe 
(depicted as a blue box) was employed to increase the specificity and sensitivity of the 
assay. (B) Relative total GHRLOS expression in a range of human human tissues. (C) 
Relative total GHRLOS expression in human cell lines (U-937 non-Hodgkin’s 
lymphoma, SW1353 chondrosarcoma, CaCo-2 colorectal adenocarcinoma, SAOS-2 
osteosarcoma, U-87 MG and U-251 MG glioblastoma,  HEK293 human embryonic 
kidney and OVCAR-3 ovarian cancer). Calculations of GHRLOS expression levels 
 - 45 - 
were performed using the standard curve method (correlating the threshold cycle 
number (CT values) and copy numbers of GHRLOS), and normalised to the expression 
of 18S ribosomal RNA. Each bar presents the mean ± standard deviation of duplicate 
reactions. 
  
Figure 8. Comparison of strand-specific GHRL and GHRLOS real-time RT-PCR 
Relative total GHRL (sense, black) and GHRLOS (antisense, grey) RNA transcript 
expression levels in human tissues and cell lines. Calculations of RNA expression 
levels were performed using the standard curve method (correlating the threshold 
cycle number (CT values) and copy numbers of GHRL and GHRLOS) normalised to 
the expression of 18S ribosomal RNA. Each bar presents the mean ± standard 
deviation of duplicate reactions. 
 
Figure 9. Structure of genes at the GHRLOS locus 
Structure of the human GHRLOS (top) and ghrelin (GHRL) (bottom) genes. Exons are 
shown as boxes and introns as lines. Genes on the positive DNA strand are displayed 
above the double-lines, while genes on the negative DNA strand are shown below. 
Arrows indicate transcription start sites of GHRLOS transcripts. Ghrelin (GHRL) 
exons are shown in grey, and GHRLOS in black. A novel exon of a putative SEC13 
variant, SEC13-T is shown as white boxes. The terminal exon 8 of TATDN2 is 
indicated by a dotted line.  
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Tables 
Table 1. Designations and sequences of oligonucleotides 
 
Name Sequence (5’-3’) GHRLOS 
Exon 
Ta (°C) PCR 
Cycles 
5’2-out-F GATGGCGATGAATGAACACTG   N/A   
5’2-out-R AATCATCTCAGGAATACCTGGA   2 60 35 
5’2-in-F ATGAATGAACACTGCGTTTGC   N/A   
5’2-in-R AAATGGAAGAGATGAGGCGC   2 61 35 
Ex1-
cRNA-F 
CATACAGTTTGAACATTTATTCGCCTCC   1   
Ex1-
cRNA-R 
CTAATACGACTCACTATAGGGAGACTCT
CTCTAAGTTTAGAAGCGCTCATCTG   
1 62 25 
3’2OF GAGAGCGCCTCATCTCTTCC   2 
                                                                     
 
3’2OR GCGAGCACAGAATTAATACGACTC   N/A 63 35 
3’2IF ATGATTTATTGGAGCTCAAAGC   2   
3’2IR GAATTAATACGACTCACTATAGGT   N/A 57 15 
3’4 TACGGAACAGAGGAGAGATGC   4 60 35 
3′-RACE-
adapter 
GCGAGCACAGAATTAATACGACTCACTA
TAGGTTTTTTTTTTTTVN 
N/A  N/A 
IPCR-out-
F 
AAATCCCACCTTTAGTCCCA   4 60 35 
IPCR-in-F CTGCCACCTGAGTGTAGAC   4 60 20 
IPCR-
ALL-R 
CACAGGCTTGGAGACTTCC   I   
Pthioate-
hex 
NNNNsNsN N/A 30 N/A 
Phospho-
dT 
P- GGCCACGCGTCGACTAGTAC(T)18 N/A 55 N/A 
GHRL-
Real-RT-
LK 
CGACTGGAGCACGAGGACACTGAGCCAG
AGAGCGCTTCTAAACTTA 
N/A N/A  
GHRL-
Real-F 
GCCCCAGCCGACAAGTG N/A 60 40 
Ito4-F CATGGAAGTCTCCAAGCCTG   I   
Ito4-R CTGCTCTACTGCCTCAATGTC   4 63 34 
GHRLOS-
Real-RT-
LK 
CGACTGGAGCACGAGGACACTGACAATC
CTCCCTGAGGTTGATCT 
4 N/A  
GHRLOS-
Real-F 
CATTGAGGCAGTAGAGCAGTTGA 4   
LK CGACTGGAGCACGAGGACACTGA N/A 60 40 
Ex4-
TaqMan 
FAM-
TGCCGAATGACCACCTACCCTGACTT- 
BHQ1    
4   
18S-Real-
F 
TTCGGAACTGAGGCCATGAT N/A   
18S-Real-
R 
CGAACCTCCGACTTTCGTTCT N/A 60 40 
F_CAGE GGGACTGCCTGTAATAGCAC   I   
R_CAGEo
ut 
CACGACTGTTGTACAAGCTC   1 60 35 
R_CAGEi
n 
GGAGGCGAATAAATGTTCAAACTG   1 61 30 
ChiOut-F TGAAAGCCCAGAAGGAGGA N/A   
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ChiOut-R TCTAAGTTTAGAAGCGCTCATCTG 1 63 35 
ChiIn-F CAGAAGGAGGACGATGTGG N/A   
ChiIn-R CACGACTGTTGTACAAGCTC 1 62 30 
UIS231-F ACAAGTTCAACGATGTGGTG N/A   
UIS231-R CAAGTGTGAATAATAACCAAGCCC N/A 55 40 
 
T7 promoter sequence in PCR primers is underlined. Linker sequence (LK) in the 
primer GHRLOS-Real-RT-LK and GHRL-Real-RT-LK is shown in bold. In primer 
3′-RACE-adapter V denotes an A/G/C residue and N denotes A/G/C. Lowercase 
letters in primer Pthioate-hex denotes phosphothioate linkages. An uppercase P in 
primer Phospho-dT indicates that the synthetic oligonucleotide was 5’ 
phosphorylated. Annealing temperatures (Ta) of oligonucleotides employed in PCR is 
shown. The GHRL or GHRLOS exon location of nucleotides are listed, while 
oligonucleotides spanning synthetic sequences (adapters and linkers) or genes other 
than GHRL and GHRLOS are denoted as N/A. 
 
 
 - 48 - 
Additional files 
Additional file 1 
File format: TIFF 
Title: Overview of GHRLOS exon 1.  
Description: This is a TIFF file showing GHRLOS transcription start sites and exon 1 
sequence. Exon 1 and exons I, II and III, all of which splice into the 106 bp exon 1, 
are depicted as black boxes. Exons with transcription start sites are indicated by 
arrows in the direction of transcription. The sequence of the 106 bp exon 1, which 
splices into upstream exons, is shaded in grey. Transcription start sites in exon 1, 
previously determined via 5’ RACE (∆) and CAGE (Cap Analysis of Gene 
Expression) (∗), are indicated, and the exact transcription start site nucleotides are 
underlined and in bold. For comparison, the sequence of the reference (sense) exon 4 
of the ghrelin gene [GenBank:NM_016362] is shown in red. GHRLOS exon 1 
sequence is shown in upper case, while intron sequence is shown in lower case.   
 
 
Additional file 2 
File format: TIFF 
Title: Ethidium bromide stained agarose gel electrophoresis of GHRLOS exon I a/b to 
4 non-quantitative RT-PCR amplicons from cultured cells and normal prostate and 
stomach tissue. 
Description: This is a TIFF file showing the expression profile of exon I a/b to 4 
amplicons in various human tissues and cell lines, indicating a complex splice pattern. 
M = MassRuler Express DNA ladder (Fermentas, Burlington, Canada).  
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Additional file 3  
File format: PDF 
Title: Compilation of exons of GHRLOS transcripts. 
Description: This is a PDF file listing exons of GHRLOS. Exon and intron sizes (bp) 
are indicated. Experimental evidence from this study and/or external references for 
each exon are shown.  
 
Additional file 4 
File format: TIFF 
Title: Overview of CAGE-aided primer walking amplicons and CAGE tags in the 3’ 
untranslated exon 8 of TATDN2 
Description: This is a PDF file showing (A) The expression pattern of transcripts 
spanning exon 8 of TATDN2 (orange) and exon 1 of GHRLOS (blue) revealed via 
cDNA primer walking (exon shown as boxes, introns as lines, and sizes in bp 
indicated above each exon). (B) CAGE tags present in the 3’ untranslated region of 
TATDN2 (H51BA34H0302-testis; H22BA47L0809-Hep G2 hepatocarcinoma; 
H21BB07A0112-Hep G2; H52BA49L1810-adrenal gland; H04BB25B1106-
cerebrum; H63BA79F2401-heart; H59BA94L1109-SK-N-AS neuroblastoma cell 
line; H08BA37K2001-kidney malignancy; H21BA90I0206-HepG2 hepatocellular 
liver carcinoma; H62BB07A0901-SK-N-AS). TATDN2 exon sequence is shown in 
beige, intron sequence in lowercase and grey, GHRLOS sequence deduced from 
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cDNA primer walking in orange, and the TATDN2 polyadenylation signal 
(AATAAA) is shown in red. 
Additional file 5 
File format: JPG 
Title: Comparison of human (h) and putative dog GHRLOS exon sequences  
Description: This is a JPEG file showing the comparison of human and putative dog 
GHRLOS exon sequences. The alignments were generated by the ClustalW program 
and drawn by BOXSHADE (http://www.ch.embnet.org/software/BOX_form.html). 
Black shading indicates conserved nucleotides. (A) Exon II (B) Exon 2 (C) Exon 3. 
 
 
Additional file 6  
File format: TIF 
Title: Overview of GHRLOS exon 4 and overlapping exons 
Description: This is a TIFF file with an overview of GHRLOS exon 4 (highlighted in 
grey) showing the overlap with sense GHRL and SEC13-T exons (boxed). GT/AG 
intron splice sites are underlined. The exon 4 polyA signal is depicted in orange font. 
A stretch of poly(A) in the genomic sequence (exon 4) resulting of frequent oligo(dT) 
mispriming during cDNA synthesis is highlighted in pink.   
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